QuVa Pharma Inc an FDA registered 503B outsourcing provider of 'ready-to-use' compounded IV products, has received a group purchasing agreement for Outsourced IV Admixture Services from Premier, a healthcare improvement company, it was reported yesterday.

This contract is intended to allow Premier members to take advantage of special pricing and terms pre-negotiated by Premier for a comprehensive range of compounded IV products effective 1 January 2019.

Stuart Hinchen, QuVa Pharma's co-founder and chief executive officer, said, 'We are delighted to receive this award by Premier. We look forward to providing our broad range of ready to use sterile products to Premier's membership. This award recognises our market leading quality record, national distribution licensing and reach, and substantial available production capacity following extensive investment in manufacturing capability in both Texas and New Jersey. Our extensive array of sterile compounded IV products, sourced from both FDA approved pharmaceutical products and active pharmaceutical ingredients as starting material, gives us unrivalled capability to service customers including in times of drug shortage.'